Adverse mucocutaneous reactions to chemotherapeutic agents - Part I;Reações tegumentares adversas relacionadas aos agentes antineoplásicos - Parte I

Anais Brasileiros de Dermatologia

Volumn 85, Issue 4, 2010, Pages 425-437

  Sanches Jr , Jose Antonio ^a   Moure, Emanuella Rosyane Duarte ^a   Criado, Paulo Ricardo ^a,b   Brandt, Hebert Roberto Clivati ^a   Pereira, Guilherme Luiz Stelko ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Division of Clinical Dermatology   (Brazil)

Author keywords

Adjuvant; Chemotherapy; Combination; Drug therapy; Skin; Skin abnormalities; Skin pigmentation

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MINOXIDIL; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; TOPOTECAN; UNINDEXED DRUG; VINCA ALKALOID;

ACNE; ADVERSE OUTCOME; ALOPECIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; ECCRINE SQUAMOUS SYRINGOMETAPLASIA; ERYTHEMA; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; NAIL DISEASE; ONYCHOLYCOSIS; REVIEW; SKIN DISEASE; STOMATITIS; SWEAT GLAND DISEASE;

EID: 78049341232     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/s0365-05962010000400003     Document Type: Review

References (70)

1. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58:545-70.
2. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367-98.
3. Remlinger KA. Cutaneous reactionsto chemotherapy drugs: the art of consultation. Arch Dermatol. 2003;139:77-81.
4. Silvares MRC, Abbade LPF, Lavezzo M, Gonçalves TM, Abbade JF. Reações cutâneas desencadeadas por drogas. An Bras Dermatol. 2008;83:227-32.
5. Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J. 1993;86:489-96.
6. Weiss RB, Baker JR Jr. Hypersensitivity reactions from antineoplastic agents. Cancer Metastasis Rev. 1987;6:413-32.
7. Alley E, Green R, Schuchter L. Cutaneous Toxicities of Cancer Therapy. Curr Opin Oncol.. 2002;14:212-6.
8. Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35:74-8. (Pubitemid 26231327)
9. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43:845-51. (Pubitemid 46366684)
10. Schneider MR, Werner S, Paus R, Wolf E. Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol. 2008;173:14-24.
11. Bouche O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol. 2005;16:1711-2.
12. Pascual JC, Banuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 2004;151:1111-2.
13. Piraccini BM, Iorizzo M. Drug reactions affecting the nail unit: diagnosis and management. Dermatol Clin. 2007;25:215-21.
14. Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol. 2006;7:45-63.
15. Piraccini BM, Iorizzo M, Antonucci A, Tosti A. Drug-induced nail abnormalities. Expert Opin Drug Saf. 2004;3:57-65.
16. Chapman S, Cohen PR. Transverse leukonychia in patients receiving cancer chemotherapy. South Med J. 1997;90:395-8. (Pubitemid 27176401)
17. Pratt CB, Skanks EC. Hyperpigmentation of nails from doxorubicin. JAMA. 1974;228:460.
18. Shah PC, Rao KR, Patel AR. Cyclophosphamide induced nail pigmentation. Br J Dermatol. 1978;98:675-80.
19. Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci. 2001;321:327-35.
20. Llombart-Cussac A, Pivot X, Spielmann M. Docetaxel chemotherapy induces transverse superficial loss of the nail plate. Arch Dermatol. 1997;133:1466-7.
21. Makris A, Mortimer P, Powles TJ. Chemotherapy induced onycholysis. Eur J Cancer. 1996;32A:374-5.
22. Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS. Onycholysis as a complication of systemic chemotherapy: a report of five cases associated with prolonged weekly palcitaxel therapy and review of the literature. Cancer. 2000;88:2367-71.
23. Gómez Vázquez M, Peteiro C, Toribio J. Neutrophilic eccrine hidradenitis heralding the onset of chronic myelogenous leukaemia. J Eur Acad Dermatol Venereol. 2003;17:328-30.
24. Brehler R, Reimann S, Bonsmann G, Metze D. Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Am J Dermatopathol. 1997;19:73-8.
25. Oono T, Matsuura H, Morizane S, Yamasaki O, Iwatsuki K. A case of infectious eccrine hidradenitis. J Dermatol. 2006;33:142-5.
26. Antonovich DD, Berke A, Grant-Kels JM, Fung M. Infectious eccrine hidradenitis caused by Nocardia. J Am Acad Dermatol. 2004;50:315-18.
27. Morice A, Penven K, Comoz F, Cribier B, Dompmartin A, Leroy D. Neutrophilic eccrine hidradenitis in a healthy patient. Ann Dermatol Venereol. 2005;132:686-8.
28. Bernstein EF, Spienvogel RL, Topolsky DL. Recurrent neutrophilic eccrine hidradenitis. Br J Dermatol. 1992;127:529-33.
29. Wenzel FG, Horn TD. Nonneoplastic disorders of the eccrine glands. J Am Acad Dermatol. 1998;38:1-17.
30. Shih IH, Huang YH, Yang CH, Yang LC, Hong HS. Childhood neutrophilic eccrine hidradenitis: a clinicopathologic and immunohistochemical study of 10 patients. J Am Acad Dermatol. 2005;52:963-6.
31. Keane FM, Munn SE, Buckley DA, Hopster D, Mufti GJ, du Vivier AW. Neutrophilic eccrine hidradenitis in two neutropaenic patients. Clin Exp Dermatol. 2001;26:162-5.
32. Belot V, Perrinaud A, Corven C, de Muret A, Lorette G, Machet L. Adult idiopathic neutrophilic eccrine hidradenitis treated with colchicine. Presse Med. 2006;35:1475-8.
33. Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol. 1996;35819-22.
34. Valks R, Fraga J, Porras-Luque J, Figuera A, Garcia-Diéz A, Fernändez-Herrera J. Chemotherapy-induced eccrine squamous syringometaplasia. Arch Dermatol. 1997;133:873-8.
35. Hurt MA, Halvorson RD, Petr FC Jr, Cooper JT Jr, Friedman DJ. Eccrine squamous syringometaplasia. A cutaneous sweat gland reaction in the histologic spectrum of 'chemotherapy-associated eccrine hidradenitis' and 'neutrophilic eccrine hidradenitis'. Arch Dermatol. 1990;126:73-7.
36. Tsuboi H, Yonemoto K, Katsuoka K. A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature. J Dermatol. 2005;32:921-5. (Pubitemid 43002078)
37. Garcia-Navarro X, Puig L, Fernández-Figueras MT, Alomar A. Eccrine squamous syringometaplasia secondary to pegylated liposomal doxorubicin. Arch Dermatol. 2008;144:1402-3.
38. Baysse L, Boralevi F, Lepreux S, Boyer A, Morel C, Léauté- Labrèze C, Taïeb A. Eccrine squamous syringometaplasia and cytomegalovirus infection. Rev Med Interne. 2003;24:394-8.
39. Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol. 2000;142:808-11.
40. Eich D, Scharffetter-Kochanek K, Eich HT, Tantcheva Poor I, Krieg T. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol. 2002;25:599-602.
41. Demirçay Z, Gürbüz O, Alpdogan TB, Yücelten D, Alpdgoan O, Kurtkaya O, et al. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol. 1997;36:593-8.
42. Baack BR, Burgdorf WHC. Chemotherapy-induced acral erythema. J Am Acad Dermatol. 1991;24:457-61.
43. Narasimhan P, Narasimhan S, Hitti IF, Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis. 2004;73:101-6.
44. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007;11:238-46.
45. Hellier I, Bessis D, Sotto A, Margueritte G, Guilhou JJ. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol. 1996;132:590-1.
46. Guenova E, Weber HO, Voykov B, Metzler G, Mitev V, Berneburg M, et al. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease. Arch Dermatol. 2008;144:1081-2.
47. Vargas-Díez E, Abajo P, Fraga J, Fernández-Herrera J, García-Díez A. Chemotherapy-induced acral erythema. Acta Derm Venereol. 1999;79:173-5.
48. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998;82:965-9. (Pubitemid 28104178)
49. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007;11:238-46.
50. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225-34.
51. Wilkes GM, Doyle D. Palmar-plantar erythrodyses thesia. Clin J Oncol Nurs. 2005;9:103-6.
52. Reynaert H, De Coninck A, Neven AM, Van Camp B, Schots R. Chemotherapy-induced acral erythema and acute graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992;10:185-7.
53. Ruiz-Genao DP, GF-Villalta MJ, Peñas PF, Fraga J, García-Díez A, Fernández-Herrera J. Pustular acral erythema in a patient with acute graft-versus-host disease. J Eur Acad Dermatol Venereol. 2003;17:550-3. (Pubitemid 37138894)
54. Katoh M, Kadota M, Nishimura Y. A case of docetaxel-induced erythrodysesthesia. J Dermatol. 2004;31:403-6.
55. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998;4:1567-71.
56. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225-34.
57. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59:524-9.
58. Duvic M. EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol. 2008;9:285-94.
59. Bianchini D, Jayanth A, Chua YJ, Cunningham D. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin Colorectal Cancer. 2008;7:33-43.
60. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169-76. (Pubitemid 34204207)
61. Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005;3:599-606. (Pubitemid 41647826)
62. McGowan D. Chemotherapy-induced oral dysfunction: a literature review. Br J Nurs. 2008:17:1422-6.
63. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology. 2003;17:1767-79.
64. Demarosi F, Bez C, Carrassi A. Prevention and treatment of chemo- and radiotherapy-induced oral mucositis. Minerva Stomatol. 2002:51:173-86.
65. Saadeh CE. Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment. Pharmacotherapy. 2005;25:540-54.
66. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820-31.
67. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;4:CD000978.
68. Sutherland S. Several therapies may prevent or reduce the severity of oral mucositis associated with cancer treatment. Evid Based Dent. 2006;7:104-5.
69. Beaven AW, Shea TC. Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies. Expert Opin Pharmacother. 2006;7:2287-99.
70. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol. 2007;18:817-26. (Pubitemid 47054077)